EXAS
Exact Sciences Corporation
Exact Sciences Corporation insider trading
Exact Sciences Corporation files with the SEC as a Services-Medical Laboratories company headquartered in Madison, WI. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.
From SEC filings
Recent EXAS insider transactions
Exact Sciences Corporation's insiders made no open-market purchases or sales in the company's most recent Form 4 filings — those filings are share grants, option exercises and dispositions back to the issuer, which are compensation rather than decisions. That absence is itself worth knowing: nobody at EXAS spent or raised their own money in the market over this stretch. Two years of open-market trades are below.
SEC Form 4 data, Q3 2024 to Q2 2026
EXAS insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 6 insiders traded EXAS on the open market: 1 purchase worth $1M and 11 sales worth $2.1M, every sale pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 8 sales ($1.8M), by 5 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | — | |
| Q1 2026 | — | — | |
| Q4 2025 | — | −$1.7M7 sales · all on a plan | |
| Q3 2025 | — | −$62.4K1 sale · all on a plan | |
| Q2 2025 | — | −$170.6K1 sale · all on a plan | |
| Q1 2025 | — | — | |
| Q4 2024 | +$1M1 buy | −$65K1 sale · all on a plan | |
| Q3 2024 | — | −$65K1 sale · all on a plan |
- Largest purchase
- +$1M of EXAS by Conroy Kevin T (President and CEO · Director) on Nov 13, 2024.
- Largest sale
- −$780K of EXAS by Zanotti Katherine S (Director) on Oct 24, 2025, under a 10b5-1 plan.
Open-market transactions through Jun 30, 2026most recent first
Orville Jacob A10b5-1
EVP, GM, Screening
−$375K
Nov 19, 2025
5,000 sh · $75.00
Herriott James10b5-1
SVP, General Counsel & Sec
−$70K
Nov 19, 2025
1,000 sh · $70.00
Baranick Brian10b5-1
EVP, GM, Precision Oncology
−$200.3K
Nov 04, 2025
2,858 sh · $70.08
Herriott James10b5-1
SVP, General Counsel & Sec
−$105.1K
Nov 04, 2025
1,500 sh · $70.08
Zanotti Katherine S10b5-1
Director
−$780K
Oct 24, 2025
12,000 sh · $65.00
Doyle James Edward10b5-1
Director
−$120K
Oct 09, 2025
2,000 sh · $60.00
Herriott James10b5-1
SVP, General Counsel & Sec
−$90K
Oct 09, 2025
1,500 sh · $60.00
Doyle James Edward10b5-1
Director
−$62.4K
Aug 13, 2025
1,485 sh · $42.02
Zanotti Katherine S10b5-1
Director
−$170.6K
Jun 13, 2025
3,207 sh · $53.20
Conroy Kevin T
President and CEO · Director
+$1M
Nov 13, 2024
19,500 sh · $51.35
Baranick Brian10b5-1
EVP, GM, Precision Oncology
−$65K
Oct 08, 2024
929 sh · $70.00
Baranick Brian10b5-1
EVP, GM, Precision Oncology
−$65K
Sep 18, 2024
929 sh · $70.00
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Nov 19, 2025 | Orville Jacob A10b5-1EVP, GM, Screening | 5,000 | $75.00 | −$375K |
| Nov 19, 2025 | Herriott James10b5-1SVP, General Counsel & Sec | 1,000 | $70.00 | −$70K |
| Nov 04, 2025 | Baranick Brian10b5-1EVP, GM, Precision Oncology | 2,858 | $70.08 | −$200.3K |
| Nov 04, 2025 | Herriott James10b5-1SVP, General Counsel & Sec | 1,500 | $70.08 | −$105.1K |
| Oct 24, 2025 | Zanotti Katherine S10b5-1Director | 12,000 | $65.00 | −$780K |
| Oct 09, 2025 | Doyle James Edward10b5-1Director | 2,000 | $60.00 | −$120K |
| Oct 09, 2025 | Herriott James10b5-1SVP, General Counsel & Sec | 1,500 | $60.00 | −$90K |
| Aug 13, 2025 | Doyle James Edward10b5-1Director | 1,485 | $42.02 | −$62.4K |
| Jun 13, 2025 | Zanotti Katherine S10b5-1Director | 3,207 | $53.20 | −$170.6K |
| Nov 13, 2024 | Conroy Kevin TPresident and CEO · Director | 19,500 | $51.35 | +$1M |
| Oct 08, 2024 | Baranick Brian10b5-1EVP, GM, Precision Oncology | 929 | $70.00 | −$65K |
| Sep 18, 2024 | Baranick Brian10b5-1EVP, GM, Precision Oncology | 929 | $70.00 | −$65K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Exact Sciences Corporation company record
- SEC industry classification
- Services-Medical Laboratories
- Headquarters
- Madison, WI
- Listed on
- Nasdaq
- SEC Central Index Key
- 0001124140
- Previously filed as
- EXACT CORP
Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.
After insiders bought EXAS
What the stock actually did in the 90 days following each open-market purchase
Don't check EXAS — let it ping you
Get told the moment an insider moves on EXAS
Pro watches Exact Sciences Corporation for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add EXAS to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.
The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.
How to read EXAS insider activity
- Open-market purchase (code P)
- An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
- Grants and option exercises (codes A, M)
- Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
- Cluster buy
- Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.
Other Health Care tickers
Questions
- Have EXAS insiders bought or sold stock recently?
- No open-market purchases or sales by Exact Sciences Corporation insiders appear in the Form 4 filings scanned for this page. Grants, option exercises and tax withholding are not counted as trades.
- How much EXAS stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 6 Exact Sciences Corporation insiders made 1 open-market purchase worth $1M and 11 sales worth $2.1M. Every one of the sales was pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 8 sales ($1.8M). The largest purchase was Conroy Kevin T buying $1M on Nov 13, 2024. The largest sale was Zanotti Katherine S selling $780K on Oct 24, 2025.
- When did an insider last buy EXAS shares?
- The most recent open-market purchase in SEC's data through Jun 30, 2026 is Conroy Kevin T (President and CEO · Director) buying $1M on Nov 13, 2024.
- Where does EXAS insider trading data come from?
- From the Form 4 filings Exact Sciences Corporation's officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.